Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Diabetes

Lixisenatide does not increase rates of CVD events

Nature Reviews Cardiology volume 13, page 63 (2016)Cite this article

Subjects

Access through your institution
Buy or subscribe

Preliminary studies have shown that glucagon-like peptide 1 (GLP-1) receptor agonists, used for the treatment of type 2 diabetes mellitus in adults, might have cardioprotective properties. Findings from the ELIXA trial published in The New England Journal of Medicine show that lixisenatide, a once-daily GLP-1 receptor agonist, has no effect on cardiovascular outcomes in patients with type 2 diabetes and acute coronary syndrome.

In total, 6,068 patients from 49 countries were enrolled into the study and followed up for a median of 25 months. A primary end point event occurred in 13.4% (n = 406) of the lixisenatide group and in 13.2% (n = 399) of the placebo group (HR 1.02, 95% CI 0.89–1.17). Statistical analyses of the primary end point events indicated that lixisenatide was noninferior to placebo (P <0.001), but not superior (P = 0.81). Treatment with lixisenatide was not associated with an increased occurrence of severe adverse events, such as hypoglycaemia or pancreatic neoplasms. However, adverse events that resulted in discontinuation of treatment occurred in more patients in the lixisenatide group (n = 347) than in the placebo group (n = 217; P <0.001).

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Pfeffer, M. A. et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med. 373, 2247–2257 (2015)

    Article  CAS  Google Scholar 

Download references

Authors
  1. Karina Huynh
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huynh, K. Lixisenatide does not increase rates of CVD events. Nat Rev Cardiol 13, 63 (2016). https://doi.org/10.1038/nrcardio.2015.199

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrcardio.2015.199

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing